Atenção:
O eduCAPES é um repositório de objetos educacionais, não sendo responsável por materiais de terceiros submetidos na plataforma. O usuário assume ampla e total responsabilidade quanto à originalidade, à titularidade e ao conteúdo, citações de obras consultadas, referências e outros elementos que fazem parte do material que deseja submeter. Recomendamos que se reporte diretamente ao(s) autor(es), indicando qual parte do material foi considerada imprópria (cite página e parágrafo) e justificando sua denúncia.
Caso seja o autor original de algum material publicado indevidamente ou sem autorização, será necessário que se identifique informando nome completo, CPF e data de nascimento. Caso possua uma decisão judicial para retirada do material, solicitamos que informe o link de acesso ao documento, bem como quaisquer dados necessários ao acesso, no campo abaixo.
Todas as denúncias são sigilosas e sua identidade será preservada. Os campos nome e e-mail são de preenchimento opcional. Porém, ao deixar de informar seu e-mail, um possível retorno será inviabilizado e/ou sua denúncia poderá ser desconsiderada no caso de necessitar de informações complementares.
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Reis, Gilmar | - |
Autor(es): dc.creator | Silva, Eduardo Augusto dos Santos Moreira | - |
Autor(es): dc.creator | Silva, Daniela Carla Medeiros | - |
Autor(es): dc.creator | Thabane, Lehana | - |
Autor(es): dc.creator | Singh, Gurmit | - |
Autor(es): dc.creator | Park, Jay J. H. | - |
Autor(es): dc.creator | Forrest, Jamie I. | - |
Autor(es): dc.creator | Harari, Ofir | - |
Autor(es): dc.creator | Santos, Castilho Vitor Quirino dos | - |
Autor(es): dc.creator | Almeida, Ana Paula Figueiredo Guimarães de | - |
Autor(es): dc.creator | Figueiredo Neto, Adhemar Dias de | - |
Autor(es): dc.creator | Savassi, Leonardo Cançado Monteiro | - |
Autor(es): dc.creator | Milagres, Aline Cruz | - |
Autor(es): dc.creator | Teixeira, Mauro Martins | - |
Autor(es): dc.creator | Simplicio, Maria Izabel Campos | - |
Autor(es): dc.creator | Ribeiro, Luciene Barra | - |
Autor(es): dc.creator | Oliveira, Rosemary | - |
Autor(es): dc.creator | Mills, Edward J. | - |
Data de aceite: dc.date.accessioned | 2025-08-21T15:27:45Z | - |
Data de disponibilização: dc.date.available | 2025-08-21T15:27:45Z | - |
Data de envio: dc.date.issued | 2021-12-08 | - |
Data de envio: dc.date.issued | 2021-12-08 | - |
Data de envio: dc.date.issued | 2020 | - |
Fonte completa do material: dc.identifier | http://www.repositorio.ufop.br/jspui/handle/123456789/14147 | - |
Fonte completa do material: dc.identifier | https://doi.org/10.1001/jamanetworkopen.2021.6468 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/1015629 | - |
Descrição: dc.description | IMPORTANCE Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are needed. OBJECTIVE To determine whether hydroxychloroquine or lopinavir-ritonavir reduces hospitalization among high-risk patients with early symptomatic COVID-19 in an outpatient setting. DESIGN, SETTING, AND PARTICIPANTS This randomized clinical trial was conducted in Brazil. Recently symptomatic adults diagnosed with respiratory symptoms from SARS-CoV-2 infection were enrolled between June 2 and September 30, 2020. The planned sample size was 1476 patients, with interim analyses planned after 500 patients were enrolled. The trial was stopped after the interim analysis for futility with a sample size of 685 patients. Statistical analysis was performed in December 2020. INTERVENTIONS Patients were randomly assigned to hydroxychloroquine (800 mg loading dose, then 400 mg daily for 9 days), lopinavir-ritonavir (loading dose of 800 mg and 200 mg, respectively, every 12 hours followed by 400 mg and 100 mg, respectively, every 12 hours for the next 9 days), or placebo. MAIN OUTCOMES AND MEASURES The primary outcomes were COVID-19–associated hospitalization and death assessed at 90 days after randomization. COVID-19–associated hospitalization was analyzed with a Cox proportional hazards model. The trial included the following secondary outcomes: all-cause hospitalization, viral clearance, symptom resolution, and adverse events. RESULTS Of 685 participants, 632 (92.3%) self-identified as mixed-race, 377 (55.0%) were women, and the median (range) age was 53 (18-94) years. A total of 214 participants were randomized to hydroxychloroquine; 244, lopinavir-ritonavir; and 227, placebo. At first interim analysis, the data safety monitoring board recommended stopping enrollment of both hydroxychloroquine and lopinavir-ritonavir groups because of futility. The proportion of patients hospitalized for COVID-19 was 3.7% (8 participants) in the hydroxychloroquine group, 5.7% (14 participants) in the lopinavir ritonavir group, and 4.8% (11 participants) in the placebo group. We found no significant differences between interventions for COVID-19–associated hospitalization (hydroxychloroquine: hazard ratio [HR], 0.76 [95% CI, 0.30-1.88]; lopinavir-ritonavir: HR, 1.16 [95% CI, 0.53-2.56] as well as for the secondary outcome of viral clearance through day 14 (hydroxychloroquine: odds ratio [OR], 0.91 [95% CI, 0.82-1.02]; lopinavir-ritonavir: OR, 1.04 [95% CI, 0.94-1.16]). At the end of the trial, there were 3 fatalities recorded, 1 in the placebo group and 2 in the lopinavir-ritonavir intervention group. CONCLUSIONS AND RELEVANCE In this randomized clinical trial, neither hydroxychloroquine nor lopinavir-ritonavir showed any significant benefit for decreasing COVID-19–associated hospitalization or other secondary clinical outcomes. This trial suggests that expedient clinical trials can be implemented in low-income settings even during the COVID-19 pandemic. | - |
Formato: dc.format | application/pdf | - |
Idioma: dc.language | en | - |
Direitos: dc.rights | aberto | - |
Direitos: dc.rights | This is an open access article distributed under the terms of the CC-BY License. Fonte: o PDF do artigo. | - |
Título: dc.title | Effect of early treatment with Hydroxychloroquine or Lopinavir and Ritonavir on risk of hospitalization among patients with COVID-19. | - |
Aparece nas coleções: | Repositório Institucional - UFOP |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: